Beijing’s Tsinghua University will invest $276M in a JV to build a new biohub in the UK’s Cambridge Science Park.
February 10, 2018
Deals and Financings
- Beijing’s Tsinghua University will invest $276 million in a JV to build a new biohub in the UK’s Cambridge Science Park;
- Jing Medicine (Shanghai) formed a $100 million collaboration to develop small molecule cancer drugs with ShanghaiTech University;
- Beijing InnoCare Pharma raised $55 million in a funding round led by Vivo Capital to develop novel drugs for cancer and autoimmune diseases;
- China’s GeneScience was a new investor in Rani Therapeutics’ latest $53 million funding for its oral drug delivery of injectible drugs;
- Cellular Biomedicine, a China-US biopharma, raised $30.6 million from Sailing Capital to support a CAR-T immunotherapy;
- Luqa Pharma of Hong Kong closed a $15 million Series B financing round to develop a portfolio of in-licensed dermatology and aesthetic products for China;
- Roivant Sciences, a Swiss-US in-licensing company, will collaborate with ArQule to develop a cancer treatment in China;
- NetVation DL Medicine, a Chengdu subsidiary of HitGen, entered a two-year research collaboration to discover new drugs for Pfizer;
- Zhejiang Haichang Biotech will develop a new formulation of a Rexahn liver cancer treatment for China use;
- China Resources Pharma acquired China rights to a long-acting treatment for prostate cancer from Sweden’s Xbrane Biopharma;
Trials and Approvals
- Hong Kong’s Golden Meditech was granted FDA GMP certification for its Houston T-Cell processing facility;
- Beijing’s BeiGene launched a Celgene cancer drug, Vidaza®, in China.
Stock Symbols: (NSDQ: CBMG) (NSDQ: ARQL) (NYSE: PFE) (NYSE American: RNN) (HK: 3320) (HK: 00801) (NSDQ: BGNE) (NSDQ: CELG)
